STOCK INFORMATION
WEB CONFERENCES
Media
Watch AB Science’s web conference replays.
Listing information
Share priceEuronext
EligibilityPEA YesSRD Yes
ISIN codeFR0010557264
ICB classification
4000 IndustryHealth Care
4500 SupSectorHealth Care
4570 SectorPharmaceuticals & Biotechnology
4577 SubSectorPharmaceuticals
Discover AB SCIENCE’s strengths, programmes and prospects.
AB SCIENCE’s strengths
A differentiated position based on unmet medical need, therapeutic innovation and control of intellectual property.
High unmet medical need and strong market potential
- The diseases in development all address high unmet medical needs (Alzheimer’s disease, amyotrophic lateral sclerosis and acute myeloid leukaemia)
- The development programmes combine diseases with strong market potential and orphan diseases
Unique mechanism of action
- The lead compound, masitinib, is a kinase inhibitor that selectively targets the immune system through mast cells and macrophages / microglia
- The new compound, AB8939, is a next-generation synthetic microtubule destabiliser capable of overcoming multidrug resistance
Secure intellectual property
- Intellectual property 100% owned by AB SCIENCE
FINANCIAL DOCUMENTS
Documents for investors
Find AB SCIENCE’s latest financial reports.
Financial year 2025
Annual report of the AB SCIENCE group as at 31 December 2025.
30 June 2025
Half-year report of the AB SCIENCE group.